Experts Recap the Most Notable Data in GU Cancers Presented During the 2026 AUA Annual Meeting
The 2026 American Urological Association (AUA) Annual Meeting in Washington, DC, highlighted a significant shift toward bladder preservation and precision medicine. Experts presented new data on gene therapies and combination treatments that may offer alternatives to invasive surgeries.
Breakthroughs in Bladder Cancer Management
Recent studies presented at the plenary session focused on treating high-risk non-muscle-invasive bladder cancer (NMIBC). Dr. Ashish M. Kamat discussed the effectiveness of detalimogene voraplasmid, a non-viral intravesical gene therapy.
Additional data from the POTOMAC study, presented by Dr. Neal Shore, demonstrated positive responses in papillary disease and improved cystectomy-free rates. These findings suggest a move toward keeping the bladder intact for more patients.
Dr. Eugene Pietzak shared results from a 37-patient study involving very high-risk T1 BCG-naive NMIBC. The use of pembrolizumab (Keytruda) combined with intravesical BCG resulted in a 92% six-month clinical complete response rate.
These advancements in checkpoint inhibitors and gene therapy are significant because they could prevent the need for radical cystectomies. For many high-risk patients, this may eliminate the need for a life-altering surgery.
The Evolution of Robotic Surgery
Surgical management is being redefined by new technology, including a new intravesical TURBT (transurethral resection of a bladder tumor) robot. This system, which has received FDA breakthrough device designation, is currently being submitted to the FDA.
Once approved, this technology could allow surgeons to perform en bloc resection of bladder tumors transurethrally. This approach is viewed as a disruptive advancement in how urologists remove tumors.
A Multidisciplinary Approach to Oncology
A recurring theme at the meeting was the necessity of collaboration. Urologists are increasingly working with medical oncology and nuclear medicine, particularly for the administration of radioligand therapies.
In the realm of prostate and kidney cancers, treatments are becoming more individualized. The use of antiandrogen treatments, radiopharmaceuticals, and targeted therapy is becoming more subtle and precise.
Progress in genetic testing is also playing a key role in selecting specific treatments. This individualized approach is being applied across various oncologic surgeries, including the use of single-port and retroperitoneal access.
Future Outlook for Urological Care
The integration of neoadjuvant and adjuvant treatments may further expand options for bladder preservation. As new robotic platforms gain FDA approval, surgical access could become less invasive.
The field is likely to see a continued move toward team-based care. Urologists may continue to lead the diagnostic process while collaborating closely with other specialists to manage complex metastatic cases.
Frequently Asked Questions
What is the potential benefit of the new TURBT robot?
The technology could allow surgeons to perform en bloc resection of bladder tumors transurethrally once it receives FDA approval.
Which combination therapy showed a 92% response rate in high-risk T1 patients?
The combination of intravenous pembrolizumab (Keytruda) and intravesical BCG demonstrated a 92% six-month clinical complete response rate in this patient group.
How is the treatment of prostate cancer becoming more individualized?
Treatment is evolving through the use of genetic testing, targeted therapy, radiopharmaceuticals, and antiandrogen treatments to select the best option for each patient.
How do you feel about the increasing role of robotic technology in life-altering surgeries?